Kallum Titchmarsh
Stock Analyst at Morgan Stanley
(4.08)
# 1,559
Out of 4,974 analysts
207
Total ratings
59.1%
Success rate
10.5%
Average return
Main Sectors:
Stocks Rated by Kallum Titchmarsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GRAL GRAIL | Maintained: Hold | $60 | $75.53 | -20.56% | 6 | Sep 15, 2026 | |
| CRL Charles River Laboratories International | Maintained: Buy | $300 | $273.11 | +9.85% | 8 | Sep 15, 2026 | |
| WAT Waters | Maintained: Hold | $430 | $410.01 | +4.88% | 6 | Sep 15, 2026 | |
| WST West Pharmaceutical Services | Maintained: Hold | $365 | $355.20 | +2.76% | 10 | Sep 15, 2026 | |
| NTRA Natera | Maintained: Buy | $355 | $341.79 | +3.86% | 7 | Sep 15, 2026 | |
| MMED MiniMed Group | Rated: Buy | $19 | $21.97 | -13.52% | 3 | Sep 3, 2026 | |
| A Agilent Technologies | Reiterated: Buy | $175 | $146.80 | +19.21% | 8 | Sep 1, 2026 | |
| STVN Stevanato Group | Rated: Hold | $20 | $21.32 | -6.19% | 13 | Aug 31, 2026 | |
| HTFL HeartFlow | Reiterated: Hold | $35 → $40 | $49.54 | -19.26% | 2 | Aug 17, 2026 | |
| TXG 10x Genomics | Rated: Hold | $37 → $40 | $70.11 | -42.95% | 7 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5.5 | $4.83 | +13.87% | 3 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $175 → $185 | $167.84 | +10.22% | 7 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $1,275 → $1,450 | $1,285.75 | +12.77% | 5 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Sell | $47 → $44 | $41.21 | +6.77% | 6 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $220 | $203.25 | +8.24% | 9 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $22 | $24.78 | -11.22% | 5 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $14 | $15.16 | -7.65% | 2 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $200 → $240 | $265.67 | -9.66% | 6 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $620 → $650 | $613.62 | +5.93% | 5 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $62.21 | +12.52% | 5 | Jul 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $9 → $13 | $16.29 | -20.20% | 4 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $68 | $75.77 | n/a | 6 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $182 | $74.32 | n/a | 12 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 → $160 | $114.72 | n/a | 15 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $15 | $5.24 | n/a | 11 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $4.63 | n/a | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $18.70 | n/a | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $260 | $319.86 | n/a | 12 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $11 | $10.86 | n/a | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $4 | $8.13 | n/a | 14 | Dec 3, 2024 |
GRAIL
Sep 15, 2026
Maintained: Hold
Price Target: $60
Current: $75.53
Upside: -20.56%
Charles River Laboratories International
Sep 15, 2026
Maintained: Buy
Price Target: $300
Current: $273.11
Upside: +9.85%
Waters
Sep 15, 2026
Maintained: Hold
Price Target: $430
Current: $410.01
Upside: +4.88%
West Pharmaceutical Services
Sep 15, 2026
Maintained: Hold
Price Target: $365
Current: $355.20
Upside: +2.76%
Natera
Sep 15, 2026
Maintained: Buy
Price Target: $355
Current: $341.79
Upside: +3.86%
MiniMed Group
Sep 3, 2026
Rated: Buy
Price Target: $19
Current: $21.97
Upside: -13.52%
Agilent Technologies
Sep 1, 2026
Reiterated: Buy
Price Target: $175
Current: $146.80
Upside: +19.21%
Stevanato Group
Aug 31, 2026
Rated: Hold
Price Target: $20
Current: $21.32
Upside: -6.19%
HeartFlow
Aug 17, 2026
Reiterated: Hold
Price Target: $35 → $40
Current: $49.54
Upside: -19.26%
10x Genomics
Aug 10, 2026
Rated: Hold
Price Target: $37 → $40
Current: $70.11
Upside: -42.95%
Aug 6, 2026
Reiterated: Hold
Price Target: $5.5
Current: $4.83
Upside: +13.87%
Aug 4, 2026
Rated: Buy
Price Target: $175 → $185
Current: $167.84
Upside: +10.22%
Aug 4, 2026
Rated: Hold
Price Target: $1,275 → $1,450
Current: $1,285.75
Upside: +12.77%
Aug 4, 2026
Rated: Sell
Price Target: $47 → $44
Current: $41.21
Upside: +6.77%
Aug 3, 2026
Reiterated: Buy
Price Target: $220
Current: $203.25
Upside: +8.24%
Jul 30, 2026
Reiterated: Hold
Price Target: $20 → $22
Current: $24.78
Upside: -11.22%
Jul 30, 2026
Reiterated: Hold
Price Target: $10 → $14
Current: $15.16
Upside: -7.65%
Jul 29, 2026
Reiterated: Hold
Price Target: $200 → $240
Current: $265.67
Upside: -9.66%
Jul 24, 2026
Reiterated: Buy
Price Target: $620 → $650
Current: $613.62
Upside: +5.93%
Jul 10, 2026
Reiterated: Buy
Price Target: $70
Current: $62.21
Upside: +12.52%
Jul 9, 2026
Rated: Hold
Price Target: $9 → $13
Current: $16.29
Upside: -20.20%
Jul 15, 2025
Reiterated: Buy
Price Target: $100 → $68
Current: $75.77
Upside: n/a
Jul 15, 2025
Reiterated: Buy
Price Target: $200 → $182
Current: $74.32
Upside: n/a
Jun 11, 2025
Reiterated: Buy
Price Target: $130 → $160
Current: $114.72
Upside: n/a
May 20, 2025
Reiterated: Hold
Price Target: $20 → $15
Current: $5.24
Upside: n/a
May 9, 2025
Reiterated: Hold
Price Target: $10
Current: $4.63
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $19
Current: $18.70
Upside: n/a
Apr 24, 2025
Reiterated: Hold
Price Target: $260
Current: $319.86
Upside: n/a
Feb 27, 2025
Reiterated: Hold
Price Target: $10 → $11
Current: $10.86
Upside: n/a
Dec 3, 2024
Reiterated: Hold
Price Target: $5 → $4
Current: $8.13
Upside: n/a